Patents Assigned to THE UNITED STATES OF AMERICA, as represented by TH
-
Patent number: 11253511Abstract: The present invention relates to the field of virology. More specifically, the present invention provides methods and compositions useful for prevention and treatment of human cytomegalovirus (CMV). In one embodiment, a pharmaceutical composition comprises (a) emetine or a derivative thereof; (b) a human cytomegalovirus (HCMV) drug; and (c) a pharmaceutically acceptable carrier. In certain embodiments, the pharmaceutical composition further comprises an adjuvant. In a specific embodiment, the HCMV drug is ganciclovir. In such embodiments, emetine is present at about 1/10 to about 1/100 the normal dosage for amebiasis.Type: GrantFiled: January 4, 2017Date of Patent: February 22, 2022Assignees: The Johns Hopkins University, THE UNITED STATES OF AMERICA, as represented by thInventors: Ravit Boger, Marc Ferrer, Juan Marugan, Andres Dulcey Garcia, Noel Terrence Southall, Xin Hu
-
Publication number: 20180224543Abstract: An embodiment can include a vessel-towed system that includes a first towing/communication interface system, e.g., a first tow cable with a fiber optic system, and spaced apart buoys for supporting the first tow cable. A first mobile structure including a first control system and first type of emitter, e.g., an attraction system, is connected to the first tow cable. A second mobile structure is provided that can include an underwater towed emitter such as an audio emulation system. The first and second emitters can be configured emit a first and second plurality of emissions for inducing a receiving entity response. The second mobile structure is coupled with the first mobile structure with a second tow cable that comprises another fiber optic cable. An automated response or manual control systems can be provided on the towing vessel and the first mobile structure adapted to operate the first and second emitters.Type: ApplicationFiled: April 3, 2018Publication date: August 9, 2018Applicant: The United States of America, as represented by th e Secretary of the NavyInventors: Robert S Lanham, William Stocke
-
Publication number: 20180208669Abstract: Provided herein are methods of inhibiting growth or proliferation of cells expressing CD38 by contacting the CD38-expressing cells with 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously. Also provided herein are methods of treating or inhibiting a hyperproliferative disorder or an autoimmune disorder in a subject by administering to the subject 1) NK cells bound to an anti-CD38 F(ab?)2 fragment and 2) an anti-CD38 antibody, in either order or simultaneously.Type: ApplicationFiled: June 15, 2015Publication date: July 26, 2018Applicants: The United States of America, as represented by th e Secretary, Dept. of Health and Human Services, Janssen Biotech, Inc.Inventors: Richard W. Childs, Maria Berg, Luis Espinoza Calderon, Kate Sasser, Ricardo Attar
-
Publication number: 20170239376Abstract: Disclosed is a compound of formula (I): wherein L, R1-R5, A, B, M, and n are as defined in the specification, as well as a method of preparing the compound. Also disclosed are a method of blood-pool imaging in a mammal and a method of imaging a lymph node in a mammal, comprising use of the compound.Type: ApplicationFiled: May 5, 2017Publication date: August 24, 2017Applicant: The United States of America, as represented by th e Secretary, Department of Health and Human ServiInventors: Xiaoyuan Chen, Lixin Lang, Gang Niu
-
Publication number: 20170136008Abstract: A method of treating ovarian cancer in a subject afflicted therewith comprising administering to the subject an effective amount of an anti-cancer agent and an effective amount of a compound having the structure:Type: ApplicationFiled: June 19, 2015Publication date: May 18, 2017Applicants: Lixte Biotechnology, Inc., The United States of America, as Represented by th e Secretary, Department of Health & Human ServiceInventors: John S. Kovach, Zhengping Zhuang, Ki-eun Chang, Matthew Hall, Michael M. Gottesman
-
Publication number: 20170058366Abstract: Disclosed herein are methods of detecting HIV-2 nucleic acids in a sample (such as from a sample infected with or suspected to be infected with HIV-2). In some examples, the methods include LAMP or RT-LAMP, while in other examples, the methods include hybridization of a probe to an HIV-2 nucleic acid, including, but not limited to real-time PCR. Sets of LAMP primers for detection of HIV-2 Group A and Group B nucleic acids are provided herein. Sets of probes and primers for real-time PCR detection of HIV-2 nucleic acids are also provided herein. Finally, primers for amplification of HIV-2 nucleic acids are provided. Also disclosed are isolated HIV-2 nucleic acids, vectors including the HIV-2 nucleic acids, and cells transformed with vectors including HIV-2 nucleic acids.Type: ApplicationFiled: February 20, 2015Publication date: March 2, 2017Applicant: The United States of America, as represented by th e Secretary, Dept. of Health and Human ServicesInventors: Kelly A. Curtis, Ae S. Youngpairoj, Sherry M. Owen, Chou-Pong Pau, Timothy C. Granade, Philip Niedzwiedz, Donna L. Rudolph
-
Publication number: 20170007685Abstract: A lymphoma cell line was engineered to express surface IgG1 Fc. These tumor cells were taken up rapidly by DCs, leading to enhanced cross-presentation of tumor-derived antigen to CD8 T cells. IgG1-Fc tumors failed to grow in vivo and prophylactic vaccination in an animal model resulted in rejection of unmanipulated tumor cells. Furthermore, IgG1-Fc tumor cells were able to slow the growth of an unmanipulated primary tumor when used as a therapeutic tumor vaccine. This demonstrates that engagement of Fc receptors by tumors expressing the Fc region of IgG1 can induce efficient and protective anti-tumor CD8+ T cell responses without prior knowledge of tumor-specific antigen.Type: ApplicationFiled: November 5, 2014Publication date: January 12, 2017Applicants: The Board of Regents of the University of Texas System, Yale University, The United States of America, as represented by th e Secretary, Department of Health and Human ServiInventors: Chandrashekhar PASARE, Scott N. FURLAN, Noah W. PALM, Arun UNNI
-
Publication number: 20160305940Abstract: The present invention relates to peptide substrates selectively recognized by botulinum toxin type A, BoNT/E, and their uses, in particular for carrying out methods for detecting, identifying and/or diagnosing botulinum toxin type E.Type: ApplicationFiled: December 9, 2013Publication date: October 20, 2016Applicants: The United States of America, as represented by th e Secretary, Department of Health & Human Service, The United States of America, as represented by th e Secretary, Department of Health & Human ServiceInventors: Dongxia Wang, Suzanne R. Kalb, John R. Barr
-
Publication number: 20160237121Abstract: Disclosed herein are compounds (such as peptides or peptide mimetics) that bind to HIV RRE RNA. In some examples, the compounds inhibit (for example, decrease) binding of Rev to the RRE RNA. In some embodiments, the compounds include two moieties, each of which bind to one of the Rev binding sites in the RRE. In some examples, the moieties include peptides or small molecules. In some examples, the peptides include an arginine-rich motif. The RRE binding compounds may be further linked to a detectable label or cargo moiety. Also disclosed are methods of treating or inhibiting HIV including administering one or more of the disclosed compounds to a subject.Type: ApplicationFiled: October 23, 2014Publication date: August 18, 2016Applicant: The United States of America, as represented by th e Secretary, Dept. of Health and Human ServicesInventors: Yun-Xing Wang, Ping Yu
-
Publication number: 20160039766Abstract: A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CB1 receptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.Type: ApplicationFiled: November 12, 2013Publication date: February 11, 2016Applicant: The United States of America, as represented by th e Secretary, Department of Health and Human ServiInventors: George Kunos, Malliga Iyer, Resat Cinar, Kenner C. Rice
-
Publication number: 20160009644Abstract: Disclosed herein are bisarylmethylthioacetamides and bisarylmethylthioethylamines useful as inhibitors of monoamine transporters. The compounds are potent and/or selective inhibitors of dopamine (DA), serotonin (5-HT), and/or norepinephrine (NE) reuptake via their respective transporters, DAT, SERT and NET. Also disclosed are methods for eliciting a wake-promoting or cognitive or attention enhancing effect and for treating substance use disorders, attention deficit (hyperactivity) disorder, depressive disorders, bipolar disorder or other neuropsychiatric disorders sleep disorders or cognitive impairment using the compounds.Type: ApplicationFiled: March 7, 2014Publication date: January 14, 2016Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICEInventors: AMY HAUCK NEWMAN, OLUYOMI M OKUNOLA-BAKARE, JIANJING CAO
-
Publication number: 20150299656Abstract: Provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating naïve T cells from a mammal, wherein the mammal is not a mouse; b) activating the naïve T cells and expanding the numbers of naïve T cells in the presence of one or more non-specific T cell stimuli, one or more cytokines, and a GSK-3beta inhibitor. Also provided are methods of producing an isolated T memory stem cell population, the method comprising a) isolating lymphocytes from a mammal; b) sorting the lymphocytes using flow cytometry into a population comprising a phenotype comprising i) CD95+, CD45RO?, and CCR7+; and ii) CD62L+ or one or more of CD27+, CD28+, CD45RA+, and CD127+ to produce an isolated T memory stem cell population. Further embodiments of the invention provide related cells, populations of cells, pharmaceutical compositions, and methods of treating or preventing cancer.Type: ApplicationFiled: September 6, 2012Publication date: October 22, 2015Applicant: The United States of America, as represented by th Secretary, Department of Health and Human ServiceInventors: Luca Gattinoni, Enrico Lugli, Mario Roederer, Nicholas P. Restifo
-
Publication number: 20140303230Abstract: The present description relates to an inhibitory RNA molecule, comprising an oligonucleotide that selectively knocks down expression of either Nanog or a Nanog pseudogene, a vector capable of encoding such inhibitory RNA molecule, pharmaceutical compositions comprising said vector, and methods of treating cancer by administration of said pharmaceutical composition.Type: ApplicationFiled: December 6, 2011Publication date: October 9, 2014Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH SECRETARY, DEPARTMENT OF HEALTHInventors: John Milburn Jessup, Jingyu Zhang
-
Publication number: 20120064038Abstract: Comparative gene analysis (CGA) was combined with pathway visualization software to identify a positive correlation between AAV6 transduction and epidermal growth factor receptor (EGFR) expression. It was found that EGFR is necessary for vector internalization and functions as a co-receptor for AAV6. The identification and characterization of AAV6's requirement of EGFR expression for high transduction activity has allowed construction of recombinant AAV6 vectors which are capable of targeting and killing specific types of head and neck tumors that because of this high EGFR activity, were until now, refractory to current therapies.Type: ApplicationFiled: September 10, 2010Publication date: March 15, 2012Applicant: The United States of America, as represented by th Secretary, Department of Health and Human ServiceInventors: John Chiorini, Melodie L. Weller
-
Publication number: 20110200556Abstract: Disclosed is a method for preventing the development of head and neck squamous cell carcinoma (HNSCC) in a mammal who is at risk for developing such carcinoma comprising administering an effective amount of a mammalian target of rapamycin (mTOR) inhibitor to the mammal. An example of such inhibitor is rapamycin.Type: ApplicationFiled: August 20, 2009Publication date: August 18, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH E SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIInventors: J. Silvio Gutkind, Panomwat Amornphimoltham, Vyomesh Patel, Alfredo Molinolo, Rakefet Czerninski
-
Publication number: 20110184003Abstract: The invention relates to compounds and methods for treating or preventing a viral infection, by administering a monophosphorylated prodrug of acyclovir or monophosphorylated derivative of an acyclovir prodrug to a subject suffering from or susceptible (to a viral infection, such as HIV infection.Type: ApplicationFiled: March 27, 2009Publication date: July 28, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THInventors: Leonid Margolis, Jan Balzarini, Christopher McGuigan, Andrea Lisco, Christophe Vanpouille, Marco Derudas
-
Publication number: 20110150870Abstract: The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.Type: ApplicationFiled: July 31, 2009Publication date: June 23, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THInventors: Christoph Rader, Ka Yin Kwong
-
Publication number: 20110150768Abstract: The present invention features compositions and methods that make use of complexes comprising one or more inhibitory nucleic acids and a targeting polypeptide, wherein the targeting polypeptide consists of a cell surface receptor ligand. The compositions can be used in methods of silencing gene expression in a cell, in delivering agents to a target cell, and in treating or preventing a disease or disorder in a subject.Type: ApplicationFiled: April 15, 2009Publication date: June 23, 2011Applicant: The United States of America, as represented by th e Secretary, Dept. of Health and Human ServicesInventors: Bira Arya, Purevdorj Olkhanud, Juan Espinoza
-
Publication number: 20110104163Abstract: The invention provides single domain antibodies and derivatives thereof that bind antigens of interest, which are stable, soluble, and do not tend to aggregate. The invention also provides methods for constructing a dAb library and methods for screening dAb libraries to identify the dAb of the invention. The invention also provide methods of treating or preventing conditions by antigen neutralization by administering the dAbs of the invention.Type: ApplicationFiled: January 7, 2009Publication date: May 5, 2011Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THInventors: Dimiter S. Dimitrov, Weizao Chen
-
Publication number: 20100119520Abstract: The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.Type: ApplicationFiled: February 21, 2008Publication date: May 13, 2010Applicant: THE UNITED STATES OF AMERICA, as represented by THInventors: Zhaochun Chen, Robert H. Purcell, Suzanne U. Emerson, Stephen H. Leppla, Mahtab Moayeri